Association Between Baseline Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Death Among Patients Tested for COVID‐19

Angiotensin‐converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) drugs may modify risk associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Therefore, we assessed whether baseline therapy with ACEIs or ARBs was associated with lower mortality, respirator...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2022-06, Vol.62 (6), p.777-782
Hauptverfasser:	Thomas, Sarah A., Puskarich, Michael, Pulia, Michael S., Meltzer, Andrew C., Camargo, Carlos A., Courtney, D. Mark, Nordenholz, Kristen E., Kline, Jeffrey A., Kabrhel, Christopher
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antiviral Agents - therapeutic use Coronaviruses COVID-19 COVID-19 - drug therapy Emergency medical care Enzymes Female Humans Intubation Kidneys Male Mechanical ventilation Mortality Patients Renal failure Renal Insufficiency - drug therapy Respiratory Insufficiency - drug therapy Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!